Transition Therapeutics Inc.
415 Yonge Street
Suite 1103
Toronto
Ontario
M5B2E7
Canada
Tel: 416-260-7770
Fax: 416-260-2886
183 articles about Transition Therapeutics Inc.
-
Opko Health Completes Acquisition Of Transition Therapeutics
8/31/2016
-
Transition Therapeutics Shareholders Approve Acquisition by Opko Health
8/26/2016
-
Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval Of The Plan Of Arrangement With Opko Health
8/26/2016
-
Opko Health to Acquire Transition Therapeutics in $60M Deal
6/30/2016
-
Transition Therapeutics Receives Notification From NASDAQ
6/3/2016
-
Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results
5/12/2016
-
Transition Therapeutics To Hold Conference Call On Third Quarter Fiscal 2016 Financial Results On Wednesday, May 11th, At 4:30 P.M. EST
5/10/2016
-
Transition Therapeutics Announces Dosing Of First Patient In Phase 2 Study Of Drug Candidate TT701
4/26/2016
-
Eli Lilly Abandons Development of Transition Therapeutics' Diabetes Candidate TT401
4/19/2016
-
Transition Therapeutics Receives Notification From NASDAQ
3/18/2016
-
Transition Therapeutics To Present At The 36th Annual Cowen Healthcare Conference
3/2/2016
-
Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results
2/10/2016
-
Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2016 Financial Results On Tuesday, February 9th, At 4:30 P.M. EST
2/8/2016
-
Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results Of Diabetes Drug Candidate TT401
2/1/2016
-
Transition Therapeutics Announces Annual General Meeting Voting Results
1/6/2016
-
Transition Therapeutics To Host Investor Day November 23 In New York
11/19/2015
-
Transition Therapeutics Announces First Quarter Fiscal 2016 Financial Results
11/11/2015
-
Transition Therapeutics To Hold Conference Call On First Quarter Fiscal 2016 Financial Results On Tuesday, November 10th, At 4:30 P.M. EST
11/2/2015
-
Transition Therapeutics Announces Agreement For Phase 2 Study Of TT701 Drug Candidate
10/30/2015
-
Transition Therapeutics Announces Presentation Of ELND005 Phase 2/3 Clinical Study Results At Clinical Trials In Alzheimer's Disease (CTAD) Conference
10/28/2015